MECHANISTIC PBPK MODELING OF CREATININE-DRUG INTERACTIONS IN CHRONIC KIDNEY DISEASE POPULATION.

被引：0
|
作者：
Takita, H. [1 ,2 ]
Scotcher, D. [2 ]
Chinnadurai, R. [3 ]
Kalra, P. [3 ]
Galetin, A. [2 ]
机构：
[1] Asahi Kasei Pharma, Shizuoka, Japan
[2] Univ Manchester, Manchester, Lancs, England
[3] Salford Royal NHS Fdn Trust, Salford, Lancs, England
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2021年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PIII-053
引用
收藏
页码：S59 / S60
页数：2
相关论文
共 50 条
  • [21] MECHANISTIC MODELS FOR COPROPORPHYRIN I AND CREATININE AS ENDOGENOUS BIOMARKERS FOR TRANSPORTER DRUG-DRUG INTERACTIONS
    Galetin, Aleksandra
    [J]. DRUG METABOLISM AND PHARMACOKINETICS, 2020, 35 (01) : S13 - S13
  • [22] Table showing dietary phosphorus/protein ratio for the Spanish population. Usefulness in chronic kidney disease
    Barril-Cuadrado, Guillermina
    Bernardita Puchulu, M.
    Sanchez-Tomero, Jose A.
    [J]. NEFROLOGIA, 2013, 33 (03): : 362 - 371
  • [23] Primary Vesicoureteral reflux and chronic kidney disease in pediatric population. What we have learnt?
    Andrioli, Veridiana
    Regacini, Rodrigo
    Aguiar, Wilson
    [J]. INTERNATIONAL BRAZ J UROL, 2020, 46 (02): : 262 - 268
  • [24] Association of the K/DOQI classification system of chronic kidney disease and mortality in a heart failure population.
    Khan, NA
    Ma, IW
    Thompson, C
    Humphries, K
    Salem, D
    Samak, MJ
    Adeera, L
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2005, 20 : 83 - 84
  • [25] Salivary Creatinine Estimation as an Alternative to Serum Creatinine in Chronic Kidney Disease Patients
    Venkatapathy, Ramesh
    Govindarajan, Vasupradha
    Oza, Nirima
    Parameswaran, Sreejith
    Dhanasekaran, Balamurali Pennagaram
    Prashad, Karthikshree V.
    [J]. INTERNATIONAL JOURNAL OF NEPHROLOGY, 2014, 2014
  • [26] Renal Transporter-Mediated Drug-Biomarker Interactions of the Endogenous Substrates Creatinine and N1-Methylnicotinamide: A PBPK Modeling Approach
    Tuerk, Denise
    Mueller, Fabian
    Fromm, Martin F.
    Selzer, Dominik
    Dallmann, Robert
    Lehr, Thorsten
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 112 (03) : 687 - 698
  • [27] PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING OF ELAGOLIX FOR PREDICTION OF DRUG-DRUG INTERACTIONS (DDIS)
    Chiney, M. S.
    Polepally, A. R.
    Nader, A. M.
    Dufek, M. B.
    Klein, C. E.
    Ng, J. W.
    Shebley, M.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S59 - S59
  • [28] Evaluation of Drug Prescribing Trends and Drug-Drug Interactions among Chronic Kidney Disease Patients
    Memon, Bilal Mustafa
    Khoso, Saleem Ahmed
    Ateya, Abeer Ali El-Sherbiny
    Eltayeb, Lienda Bashier
    [J]. JOURNAL OF BIOCHEMICAL TECHNOLOGY, 2022, 13 (03) : 63 - 66
  • [29] Adverse Drug Events in Patients with Chronic Kidney Disease Associated with Multiple Drug Interactions and Polypharmacy
    Sommer, Julia
    Seeling, Andreas
    Rupprecht, Harald
    [J]. DRUGS & AGING, 2020, 37 (05) : 359 - 372
  • [30] Adverse Drug Events in Patients with Chronic Kidney Disease Associated with Multiple Drug Interactions and Polypharmacy
    Julia Sommer
    Andreas Seeling
    Harald Rupprecht
    [J]. Drugs & Aging, 2020, 37 : 359 - 372
12345